What it's for (Indications)
- Amlodipine + Indapamide fixed-dose combination is indicated for the treatment of essential hypertension in adult patients.
- This combination therapy is typically prescribed for individuals whose blood pressure is not adequately controlled by monotherapy with either amlodipine or indapamide, or for those already controlled on separate tablets of amlodipine and indapamide who would benefit from a simplified regimen to improve adherence.
- Its efficacy lies in combining two distinct antihypertensive mechanisms, a calcium channel blocker and a thiazide-like diuretic, to achieve optimal blood pressure reduction and improve cardiovascular outcomes.
- The use is strictly for primary hypertension, not for secondary causes unless specifically addressed.
- This combination offers a comprehensive approach to managing elevated blood pressure, leveraging complementary pharmacological actions to achieve target blood pressure levels more effectively.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for amlodipine + indapamide fixed-dose combination, such as Natrilam MR 5 mg/1.5 mg, is one tablet orally once daily. This medication should be taken preferably in the morning. The modified-release formulation of indapamide allows for sustained therapeutic effects throughout the 24-hour dosing interval, contributing to consistent blood pressure control. Dosage adjustments for specific patient populations, particularly those with renal or hepatic impairment, require careful consideration and clinical judgment. For patients with mild to moderate renal impairment, dose adjustment may not be immediately necessary but close monitoring for adverse effects and efficacy is warranted, with strict caution for patients with a creatinine clearance below 60 mL/min. In severe renal impairment (creatinine clearance <30 mL/min) or anuria, this combination is contraindicated. Hepatic impairment necessitates cautious use due to the metabolism of amlodipine and the potential for electrolyte disturbances, with severe hepatic impairment being an absolute contraindication. The decision regarding initial dose and titration should always be guided by the patient's individual response to treatment, tolerance profile, and the severity of their hypertension, ensuring that the lowest effective dose is used. |
Safety & Warnings
Common Side Effects
- The concomitant administration of amlodipine and indapamide can lead to a range of side effects, generally reflecting the profiles of the individual components.
- Common adverse reactions associated with amlodipine include peripheral edema (ankle swelling), headache, dizziness, flushing (sensation of warmth and redness), and palpitations, primarily due to its potent vasodilatory effects.
- Fatigue and somnolence may also occur.
- Indapamide frequently causes electrolyte disturbances such as hypokalemia (low potassium), hyponatremia (low sodium), and less commonly hypomagnesemia or hypochloremic alkalosis, necessitating regular electrolyte monitoring.
- Other indapamide-related effects can include hyperglycemia (elevated blood glucose), hyperuricemia (elevated uric acid levels, potentially precipitating gout attacks), orthostatic hypotension (dizziness upon standing), and gastrointestinal upset (e.
- g.
- , nausea, constipation, dry mouth).
- Dermatological reactions like rash or photosensitivity may also occur.
- Rare but serious adverse effects may include agranulocytosis, aplastic anemia, pancreatitis, or severe dermatological reactions (e.
- g.
- , Stevens-Johnson syndrome, toxic epidermal necrolysis) for indapamide, and hepatic enzyme elevations or jaundice for amlodipine.
- Patients should be advised to report any persistent, severe, or unusual symptoms to their healthcare provider for prompt evaluation and management.
Serious Warnings
- Black Box Warning: **Serious Warnings:** There is currently no specific FDA-mandated Black Box Warning for the fixed-dose combination of amlodipine and indapamide, nor for the individual components when used as monotherapy. However, healthcare professionals and patients should be acutely aware of several serious risks associated with this medication, which warrant careful monitoring and management due to their potential for severe patient harm. **1. Electrolyte Disturbances:** The indapamide component, a potent thiazide-like diuretic, carries a significant risk of inducing clinically relevant hypokalemia (low potassium levels) and hyponatremia (low sodium levels). These electrolyte imbalances can lead to severe complications, including life-threatening cardiac arrhythmias (particularly in the context of QT prolongation) or neurological dysfunction (e.g., confusion, seizures). Regular and diligent monitoring of serum electrolytes is crucial, particularly at treatment initiation, during dose adjustments, and in patients at higher risk such as the elderly, those with cirrhosis, or individuals on concomitant medications affecting electrolyte balance (e.g., corticosteroids, cardiac glycosides, laxatives). **2. Renal Impairment and Worsening Renal Function:** Use in patients with existing renal impairment requires extreme caution. Indapamide's effectiveness diminishes, and the risk of adverse effects, including further electrolyte derangements and fluid accumulation, increases significantly as renal function declines. In severe renal impairment (creatinine clearance < 30 mL/min) or anuria, this combination is strictly contraindicated due to potential accumulation of the active ingredients and exacerbated toxicities. **3. Hepatic Impairment:** Both amlodipine and indapamide are extensively metabolized by the liver. Amlodipine's half-life is substantially prolonged in patients with hepatic impairment, leading to increased systemic exposure and a heightened potential for dose-dependent adverse effects. Indapamide can precipitate hepatic encephalopathy in severe cases of liver dysfunction. Therefore, this combination is contraindicated in severe hepatic impairment, and caution is warranted in patients with mild to moderate impairment. **4. Symptomatic Hypotension:** Initiation of therapy or dose titration can lead to excessive reductions in blood pressure, resulting in symptomatic hypotension (e.g., dizziness, lightheadedness, syncope), particularly in volume-depleted patients (e.g., due to diuretic use, low-salt diet, vomiting, diarrhea). Patients should be advised on the symptoms of hypotension and monitored accordingly, especially during the initial phases of treatment.
- Several critical warnings are associated with the use of amlodipine + indapamide.
- **Electrolyte Imbalance:** Close monitoring of serum electrolytes, especially potassium and sodium, is essential due to the indapamide component, which can induce hypokalemia (a significant risk factor for cardiac arrhythmias, particularly Torsades de Pointes) and hyponatremia.
- This risk is amplified in elderly patients, those on low-salt diets, patients with hepatic cirrhosis, or those receiving concomitant medications like corticosteroids or stimulant laxatives.
- **Renal Impairment:** The combination should be used with extreme caution in patients with pre-existing renal impairment, as indapamide's efficacy diminishes and its potential for adverse effects increases with declining renal function.
- Severe renal insufficiency (creatinine clearance <30 mL/min) is a contraindication.
- **Hepatic Impairment:** Both components are metabolized in the liver.
- Amlodipine's half-life is significantly prolonged in hepatic impairment, leading to increased systemic exposure.
- Indapamide can precipitate hepatic encephalopathy in severe cases; therefore, caution is advised, and severe hepatic impairment is a contraindication.
- **Hypotension:** Excessive blood pressure reduction, particularly at treatment initiation or dose escalation, can lead to symptomatic hypotension, especially in volume-depleted patients, those with severe sodium depletion, or patients with a compromised left ventricular function.
- **Diabetes Mellitus:** Indapamide may impair glucose tolerance, potentially unmasking latent diabetes or worsening glycemic control in existing diabetics; therefore, regular blood glucose monitoring is recommended.
- **Gout:** Indapamide can increase serum uric acid levels, potentially precipitating acute gout attacks in susceptible individuals.
- **Sulphanamide Hypersensitivity:** Due to indapamide being a sulfonamide derivative, patients with a known allergy to sulfonamides may exhibit cross-reactivity.
- **Photosensitivity:** Patients should be advised to protect their skin from sun exposure due to the risk of photosensitivity reactions with indapamide.
- **Pregnancy and Lactation:** This combination is generally not recommended during pregnancy or breastfeeding due to potential fetal/infant harm and lack of adequate safety data.
- Alternatives should be considered.
- **Cardiac Considerations:** Amlodipine should be used with caution in patients with heart failure due to the potential for increased peripheral edema, and in patients with severe aortic stenosis or cardiogenic shock where vasodilatation may be detrimental.
How it Works (Mechanism of Action)
Amlodipine + Indapamide represents a synergistic antihypertensive combination, each component acting via distinct pharmacological pathways to achieve comprehensive blood pressure reduction. **Amlodipine**, a dihydropyridine calcium channel blocker, exerts its antihypertensive effect primarily through direct relaxation of vascular smooth muscle, leading to a profound reduction in peripheral vascular resistance and, consequently, systemic blood pressure. It selectively blocks the influx of calcium ions into vascular smooth muscle cells and cardiac muscle cells through L-type voltage-dependent calcium channels. This arterial vasodilation reduces afterload, thereby lowering myocardial oxygen demand and improving blood flow. Amlodipine's slow onset and prolonged duration of action contribute to its once-daily dosing regimen and sustained blood pressure control without causing significant reflex tachycardia. **Indapamide**, a chlorosulphamoyl diuretic with properties similar to thiazide diuretics, lowers blood pressure through multiple mechanisms. Its primary diuretic action involves inhibiting the reabsorption of sodium and chloride ions in the cortical diluting segment of the renal tubules, promoting diuresis and natriuresis, which leads to a reduction in plasma and extracellular fluid volume. Additionally, indapamide possesses a direct vasodilatory effect on peripheral arterioles, independent of its diuretic action, which contributes significantly to its antihypertensive efficacy by reducing peripheral vascular resistance and arterial stiffness. The sustained-release formulation of indapamide (MR) ensures a smoother and more prolonged diuretic and vasodilatory effect, reducing the risk of sudden electrolyte shifts and maintaining consistent antihypertensive control over a 24-hour period. The combination leverages these complementary actions, with amlodipine primarily targeting vascular resistance and indapamide affecting both fluid volume and vascular tone, resulting in a more potent and comprehensive antihypertensive response than either agent alone.